News

MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
CVS Caremark drops coverage of popular weight loss drug
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
Even as prices drop, it's difficult to keep up with demand for new obesity drugs
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...